Taxanes in cancer treatment: Activity, chemoresistance and its overcoming

L Mosca, A Ilari, F Fazi, YG Assaraf, G Colotti - Drug Resistance Updates, 2021 - Elsevier
Since 1984, when paclitaxel was approved by the FDA for the treatment of advanced
ovarian carcinoma, taxanes have been widely used as microtubule-targeting antitumor …

Natural products as multidrug resistance modulators in cancer

A Kumar, V Jaitak - European journal of medicinal chemistry, 2019 - Elsevier
Cancer is a prominent cause of death globally. Currently, many drugs that are in clinical
practice are having a high prevalence of side effect and multidrug resistance. Risk of tumors …

TFAP2C-mediated lncRNA PCAT1 inhibits ferroptosis in docetaxel-resistant prostate cancer through c-Myc/miR-25-3p/SLC7A11 signaling

X Jiang, S Guo, M Xu, B Ma, R Liu, Y Xu… - Frontiers in …, 2022 - frontiersin.org
Recent evidence has shown that the induction of ferroptosis is a new therapeutic strategy for
advanced prostate cancer (PCa) when used as a monotherapy or in combination with …

PI3K-AKT-mTOR and NFκB pathways in ovarian cancer: implications for targeted therapeutics

A Ghoneum, N Said - Cancers, 2019 - mdpi.com
Ovarian cancer is the most lethal gynecologic malignancy in the United States, with an
estimated 22,530 new cases and 13,980 deaths in 2019. Recent studies have indicated that …

Mechanisms of taxane resistance

SM Maloney, CA Hoover, LV Morejon-Lasso… - Cancers, 2020 - mdpi.com
Simple Summary Drug resistance is prevalent in many types of cancer and decreases
patient survival. The taxanes are anti-mitotic chemotherapeutic agents, widely used since …

Docetaxel: An update on its molecular mechanisms, therapeutic trajectory and nanotechnology in the treatment of breast, lung and prostate cancer

M Imran, S Saleem, A Chaudhuri, J Ali… - Journal of Drug Delivery …, 2020 - Elsevier
Amongst the various microtubule-targeting agents, Docetaxel (DTX) has gained immense
attention in cancer chemotherapy due to its good therapeutic index. DTX belongs to the …

Current and emerging therapies for neuroendocrine prostate cancer

BR Alabi, S Liu, T Stoyanova - Pharmacology & Therapeutics, 2022 - Elsevier
Neuroendocrine prostate cancer is a histological variant of prostate cancer that is
characterized by aggressiveness, poor clinical outcomes, and expression of neuroendocrine …

The breast cancer stem cells traits and drug resistance

Q Zheng, M Zhang, F Zhou, L Zhang… - Frontiers in …, 2021 - frontiersin.org
Drug resistance is a major challenge in breast cancer (BC) treatment at present.
Accumulating studies indicate that breast cancer stem cells (BCSCs) are responsible for the …

Role of noncoding RNA in drug resistance of prostate cancer

L Ding, R Wang, D Shen, S Cheng, H Wang, Z Lu… - Cell death & …, 2021 - nature.com
Prostate cancer is one of the most prevalent forms of cancer around the world. Androgen-
deprivation treatment and chemotherapy are the curative approaches used to suppress …

Combination treatment of docetaxel with caffeic acid phenethyl ester suppresses the survival and the proliferation of docetaxel-resistant prostate cancer cells via …

YK Fu, BJ Wang, JC Tseng, SH Huang, CY Lin… - Journal of biomedical …, 2022 - Springer
Background Docetaxel has been approved by USFDA as a first-line treatment for castration-
resistant prostate cancer (CRPC) patients. Patients receiving androgen deprivation therapy …